Stock IPSEY IPSEN S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ipsen S.A. OTC Markets

Equities

IPSEY

US4626292050

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 14:41:09 2024-07-17 EDT 		5-day change 1st Jan Change
30.38 USD -0.26% Intraday chart for Ipsen S.A. +2.38% +3.05%
07-11 CAC40: maintains gains after reassuring US inflation figures CF
07-11 CAC40: rise without volume, W-Street at its zenith but falls back CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,560 5,609 6,621 8,279 8,912 9,185 - -
Enterprise Value (EV) 1 7,675 6,139 6,758 7,894 8,860 8,702 8,046 7,336
P/E ratio -130 x 10.3 x 10.4 x 12.9 x 14 x 14.5 x 13.1 x 11.8 x
Yield 1.27% 1.47% 1.49% 1.19% 1.11% 1.1% 1.09% 1.1%
Capitalization / Revenue 2.55 x 2.16 x 2.31 x 2.74 x 2.85 x 2.66 x 2.49 x 2.34 x
EV / Revenue 2.98 x 2.37 x 2.36 x 2.61 x 2.83 x 2.52 x 2.18 x 1.87 x
EV / EBITDA 8.13 x 6.28 x 5.8 x 5.86 x 10.1 x 7.4 x 6.41 x 5.49 x
EV / FCF 15.9 x 8.9 x 8.31 x 9.02 x 12.5 x 15.2 x 10.8 x 9.14 x
FCF Yield 6.3% 11.2% 12% 11.1% 8.02% 6.59% 9.26% 10.9%
Price to Book 3.78 x 2.67 x 2.42 x - 2.36 x 2.16 x 1.88 x 1.63 x
Nbr of stocks (in thousands) 83,035 82,601 82,243 82,380 82,599 82,599 - -
Reference price 2 79.00 67.90 80.50 100.5 107.9 111.2 111.2 111.2
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,576 2,592 2,869 3,025 3,128 3,458 3,691 3,933
EBITDA 1 943.8 977.5 1,166 1,348 881.4 1,177 1,254 1,335
EBIT 1 782.6 829.3 1,011 1,115 1,001 1,013 1,103 1,196
Operating Margin 30.38% 32% 35.25% 36.87% 32.01% 29.3% 29.88% 30.41%
Earnings before Tax (EBT) 1 -38.5 528.8 814.6 705.9 761.5 810.1 899.5 999.9
Net income 1 -50.7 548 646.6 647.5 647.2 637.3 709.4 788.1
Net margin -1.97% 21.15% 22.54% 21.4% 20.69% 18.43% 19.22% 20.04%
EPS 2 -0.6100 6.570 7.760 7.810 7.730 7.670 8.493 9.423
Free Cash Flow 1 483.2 689.9 813.2 874.8 710.9 573.3 745.2 802.6
FCF margin 18.76% 26.62% 28.35% 28.92% 22.73% 16.58% 20.19% 20.41%
FCF Conversion (EBITDA) 51.2% 70.58% 69.74% 64.88% 80.66% 48.73% 59.41% 60.11%
FCF Conversion (Net income) - 125.89% 125.77% 135.1% 109.84% 89.96% 105.05% 101.85%
Dividend per Share 2 1.000 1.000 1.200 1.200 1.200 1.226 1.211 1.221
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1
Net sales 1 1,347 1,268 1,323 1,350 727.4 791.2 1,519 687.9 745.8 1,434 774.8 816.4 1,591 741.9 794.7 1,537 772.4 818.5 1,591 822.4 835.2 1,726
EBITDA - - - - 320.9 320.9 - - - - - - - - - - - - - - - -
EBIT 395.1 410.2 419.1 479.8 - - 531.5 - - 568 - - 547.4 - - 523.2 - - 477.8 - - 520
Operating Margin 29.34% 32.34% 31.67% 35.53% - - 35% - - 39.62% - - 34.4% - - 34.05% - - 30.03% - - 30.13%
Earnings before Tax (EBT) -321.4 270.1 258.7 400.9 - - 413.7 - - - - - - - - - - - - - - -
Net income -271.3 222.7 325.3 304 - - 342.6 - - - - - 253.2 - - - - - - - - -
Net margin -20.15% 17.56% 24.58% 22.51% - - 22.56% - - - - - 15.91% - - - - - - - - -
EPS -3.250 2.660 3.910 3.640 - - 4.120 - - - - - 3.070 - - 2.350 - - 5.380 - - 3.660
Dividend per Share - - - - - - - - - - - - 1.200 - - - - - - - - -
Announcement Date 2/13/20 7/30/20 2/11/21 7/29/21 11/11/21 2/11/22 2/11/22 4/27/22 7/28/22 7/28/22 10/27/22 2/9/23 2/9/23 4/27/23 7/27/23 7/27/23 10/26/23 2/8/24 2/8/24 4/24/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,116 531 138 - - - - -
Net Cash position 1 - - - 385 52.9 483 1,139 1,849
Leverage (Debt/EBITDA) 1.182 x 0.5427 x 0.1182 x - - - - -
Free Cash Flow 1 483 690 813 875 711 573 745 803
ROE (net income / shareholders' equity) 31.3% 28.3% 26.5% 28.7% 21.4% 17.9% 16.7% 15.9%
ROA (Net income/ Total Assets) - 12.7% 13.9% 16.5% 12.8% 10.4% 10.5% 10.1%
Assets 1 - 4,312 4,660 3,933 5,046 6,152 6,749 7,831
Book Value Per Share 2 20.90 25.40 33.30 - 45.60 51.40 59.30 68.10
Cash Flow per Share 2 7.550 9.250 10.90 11.70 10.40 10.40 11.30 13.80
Capex 1 145 81.4 96 96.6 116 118 117 126
Capex / Sales 5.61% 3.14% 3.35% 3.19% 3.72% 3.4% 3.18% 3.21%
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ipsen S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
111.2 EUR
Average target price
127.3 EUR
Spread / Average Target
+14.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.35% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.12% 597B
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.10% 377B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.47% 319B
ABBVIE INC. Stock AbbVie Inc.
+13.10% 310B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.17% 247B
NOVARTIS AG Stock Novartis AG
+14.06% 228B
AMGEN INC. Stock Amgen Inc.
+16.54% 180B
PFIZER, INC. Stock Pfizer, Inc.
+4.31% 170B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IPN Stock
  4. IPSEY Stock
  5. Financials Ipsen S.A.